Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  Adjei, Alexander ^a   Narh Bana, Solomon ^a   Amu, Alberta ^a   Kukula, Vida ^a   Nagai, Richard Afedi ^a   Owusu Agyei, Seth ^b   Oduro, Abraham ^c   Macete, Eusebio ^d   Abdulla, Salim ^e   Halidou, Tinto ^f   Sie, Ali ^g   Osei, Isaac ^c   Sevene, Esperance ^d   Asante, Kwaku Poku ^b   Mulokozi, Abdunoor ^e   Compaore, Guillaume ^g   Valea, Innocent ^f   Adjuik, Martin ^h   Baiden, Rita ^h   Ogutu, Bernhards ^h   Binka, Fred ^h,i   Gyapong, Margaret ^a   more..

^a Dodowa Health Research Centre   (Ghana)

^b KINTAMPO HEALTH RESEARCH CENTRE   (Ghana)

^c NAVRONGO HEALTH RESEARCH CENTRE   (Ghana)

^d Manhiça Health Research Center   (Mozambique)

^e IFAKARA HEALTH INSTITUTE   (Tanzania)

^f Nanoro Health Research Centre   (Burkina Faso)

^g CENTRE DE RECHERCHE EN SANTÉ DE NOUNA   (Burkina Faso)

^h Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Ghana)

ⁱ UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Ghana)

Author keywords

Artemisinin based combination therapy; Dihydroartemisinin piperaquine; Effectiveness; Treatment outcome; Uncomplicated malaria

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BURKINA FASO; CHILD; COHORT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; GHANA; HEALTH CARE FACILITY; HUMAN; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA; MALARIA RAPID TEST; MALE; MICROSCOPY; MOZAMBIQUE; OBSERVATIONAL STUDY; PHASE 4 CLINICAL TRIAL; TANZANIA; VOMITING; MIDDLE AGED; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ARTEMISININS; BURKINA FASO; CHILD; CHILD, PRESCHOOL; FEMALE; GHANA; HEALTH FACILITIES; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA; MALE; MIDDLE AGED; MOZAMBIQUE; QUINOLINES; TANZANIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84961333954     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1099-7     Document Type: Article

References (37)

1. WHO. Guidelines for the Treatment of Malaria. 2nd edn. Geneva: World Health Organization; 2010. whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf. Accessed Nov 2014.
2. WHO. World Malaria Report 2014. Geneva: World Health Organization; 2014. http://www.who.int/malaria/⋯/world-malaria-report-2014/wmr-2014-no-profile. Accessed Dec 2014.
3. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, Ilett KF, et al. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2011;55:5306-13.
4. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77:181-92.
5. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day NP, et al. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother. 2008;52:1052-61.
6. Rijken MJ, McGready R, Phyo AP, Lindegardh N, Tarning J, Laochan N, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2011;55:5500-6.
7. Tarning J, Zongo I, Some FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91:497-505.
8. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009;53:3837-46.
9. Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansané A, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J. 2009;8:200.
10. Reuter SE, Upton RN, Evans AM, Navaratnam V, Olliaro PL. Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother. 2015;70:868-76.
11. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012;11:270.
12. Tjitra E, Hasugian AR, Siswantoro H, Prasetyorini B, Ekowatiningsih R, Yusnita EA, et al. Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar J. 2012;11:153.
13. Olliaro P, Djimdé A, Dorsey G, Karema C, Martensson A, Ndiaye JL, et al. Hematologic parameters in pediatric uncomplicated plasmodium falciparum malaria in Sub-Saharan Africa. Am J Trop Med Hyg. 2011;85:619-25.
14. Zongo I, Somé FA, Somda SAM, Parikh S, Rouamba N, Rosenthal PJ, et al. Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine. PLoS One. 2014;9:e103200.
15. Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, et al. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis. 2013;207:1646-54.
16. Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg. 2007;101:858-66.
17. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS ONE. 2008;3:e2390.
18. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis. 2007;45(45):1453-61.
19. Karema C, Fanello CI, Van Overmeir C, Van Geertruyden JP, van Doren W, Ngamije D, et al. Safety and efficacy of dihydroartemisinin/piperaquine [Artekin (R)] for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg. 2006;100:1105-11.
20. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials. 2007;2:e20.
21. Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J. 2014;13:33.
22. Baiden R, Oduro A, Halidou T, Gyapong M, Sie A, Macete E, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J. 2015;14:160.
23. INDEPTH Network: (assessed on 30th November 2015, http://www.indepth-network.org).
24. Gyapong M, Sarpong D, Awini E, Manyeh AK, Tei D, Odonkor G, et al. Profile: the Dodowa HDSS. Int J Epidemiol. 2013;42:1686-96.
25. Sacoor C, Nhacolo A, Nhalungo D, Aponte JJ, Bassat Q, Augusto O, et al. Profile: Manhiça Health Research Centre (Manhiça HDSS). Int J Epidemiol. 2013;42:1309-18.
26. Oduro AR, Wak G, Azongo D, Debpuur C, Wontuo P, Kondayire F, et al. Profile of the Navrongo health and demographic surveillance system. Int J Epidemiol. 2012;41:968-76.
27. Derra K, Rouamba E, Kazienga A, Ouedraogo S, Tahita MC, Sorgho H, et al. Profile: Nanoro health and demographic surveillance system. Int J Epidemiol. 2012;41:1293-301.
28. Sie A, Louis VR, Gbangou A, Muller O, Niamba L, Stieglbauer G, et al. The health and demographic surveillance system (HDSS) in Nouna, Burkina Faso, 1993-2007. Glob health Action. 2010;3:5284.
29. Kintampo Health Research Center. Brief Introduction to Kintampo HDSS. http://www.indepth-network.org/Profiles/kintampo-hdss-2013.pdf. Accessed 15 Nov 2014.
30. Rufiji Health and Demographic Surveillance Site, Tanzania. Brief Description of Rufiji HDSS. http://www.indepth-network.org/Profiles/rufiji-hdss-2013.pdf. Accessed 15 Nov 2014.
31. The Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011;8:e1001119.
32. The WorldWide Antimalarial Resistance Network (WWARN) DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10:e1001564.
33. WHO: Guidelines for the Treatment of Malaria. 3rd edn. Geneva: World Health Organization; 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/). Accessed May 2015.
34. How to use a rapid diagnostic test (RDT): A guide for training at a village and clinic level. The Quality Assurance Project and the World Health Organization, Bethesda and Geneva, 2009. http://www.wpro.who.int/malaria/NR/rdonlyres/A5557149-BB4E-4A26-9CBA-996DA92FC8A4/0/RDTgeneric4bgeneric.pdf. Accessed Oct 2014.
35. Zwang J, Ndiaye JL, Djimde A, Dorsey G, Martensson A, Karema C, et al. Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Malar J. 2012;11:25.
36. Ignatius CM, Emeka EN, Blessing NE. Effect of malaria parasitaemia on liver enzyme tests. Int J Trop Med. 2008;3:49-52.
37. Sharma M, Nand N, Kumar H, Suman L. Evaluation of liver functions in falciparum malaria. JIMSA. 2012;25:229-30.